Lineage Cell Therapeutics Inc.
OpRegenĀ® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity[...]
03/30/2024 | Press release | Distributed by Public on 03/30/2024 00:43
Please select the service you want to use:
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact